Current and historical daily PE Ratio for Royalty Pharma PLC (
) from 2020 to Apr 26 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Royalty Pharma PLC stock (RPRX) PE ratio as of Apr 26 2024 is 11.2.
More Details
Royalty Pharma PLC (RPRX) PE Ratio (TTM) Chart
Royalty Pharma PLC (RPRX) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 973
- 1
- 2
- 3
- 4
- 5
- 6
- 11
| Royalty Pharma PLC PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-26 | 11.2 | 2024-02-22 | 12.3 |
| 2024-04-25 | 11.2 | 2024-02-21 | 12.4 |
| 2024-04-24 | 11.1 | 2024-02-20 | 12.0 |
| 2024-04-23 | 11.0 | 2024-02-16 | 11.9 |
| 2024-04-22 | 11.0 | 2024-02-15 | 11.9 |
| 2024-04-19 | 11.2 | 2024-02-14 | 11.6 |
| 2024-04-18 | 11.1 | 2024-02-13 | 11.6 |
| 2024-04-17 | 11.0 | 2024-02-12 | 11.5 |
| 2024-04-16 | 10.9 | 2024-02-09 | 11.6 |
| 2024-04-15 | 11.2 | 2024-02-08 | 11.4 |
| 2024-04-12 | 11.2 | 2024-02-07 | 11.6 |
| 2024-04-11 | 11.5 | 2024-02-06 | 12.0 |
| 2024-04-10 | 11.7 | 2024-02-05 | 11.0 |
| 2024-04-09 | 11.8 | 2024-02-02 | 11.2 |
| 2024-04-08 | 11.6 | 2024-02-01 | 11.4 |
| 2024-04-05 | 11.6 | 2024-01-31 | 11.3 |
| 2024-04-04 | 11.4 | 2024-01-30 | 11.4 |
| 2024-04-03 | 11.4 | 2024-01-29 | 11.5 |
| 2024-04-02 | 11.7 | 2024-01-26 | 11.6 |
| 2024-04-01 | 11.9 | 2024-01-25 | 11.6 |
| 2024-03-28 | 12.1 | 2024-01-24 | 11.5 |
| 2024-03-27 | 12.1 | 2024-01-23 | 11.7 |
| 2024-03-26 | 12.0 | 2024-01-22 | 11.6 |
| 2024-03-25 | 12.0 | 2024-01-19 | 11.5 |
| 2024-03-22 | 12.0 | 2024-01-18 | 11.1 |
| 2024-03-21 | 12.1 | 2024-01-17 | 11.2 |
| 2024-03-20 | 12.1 | 2024-01-16 | 11.3 |
| 2024-03-19 | 12.0 | 2024-01-12 | 11.3 |
| 2024-03-18 | 11.9 | 2024-01-11 | 11.3 |
| 2024-03-15 | 11.9 | 2024-01-10 | 11.4 |
| 2024-03-14 | 11.8 | 2024-01-09 | 11.2 |
| 2024-03-13 | 11.9 | 2024-01-08 | 11.1 |
| 2024-03-12 | 12.0 | 2024-01-05 | 10.9 |
| 2024-03-11 | 11.9 | 2024-01-04 | 11.0 |
| 2024-03-08 | 12.1 | 2024-01-03 | 11.0 |
| 2024-03-07 | 11.9 | 2024-01-02 | 11.2 |
| 2024-03-06 | 11.8 | 2023-12-29 | 11.2 |
| 2024-03-05 | 11.7 | 2023-12-28 | 11.1 |
| 2024-03-04 | 11.9 | 2023-12-27 | At Loss |
| 2024-03-01 | 11.9 | 2023-12-26 | At Loss |
| 2024-02-29 | 12.0 | 2023-12-22 | At Loss |
| 2024-02-28 | 12.2 | 2023-12-21 | At Loss |
| 2024-02-27 | 12.4 | 2023-12-20 | At Loss |
| 2024-02-26 | 12.4 | 2023-12-19 | At Loss |
| 2024-02-23 | 12.3 | 2023-12-18 | At Loss |
Royalty Pharma PLC (RPRX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Royalty Pharma PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BMVP7Y09
Share Class Description:
RPRX: Class ACompare
Compare
Traded in other countries / regions
RPRX.USARPRX.MexicoRPD.Germany IPO Date
2020-06-16Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers